尿液富含亮氨酸α-2糖蛋白1(LRG1)预测2型糖尿病患者进展至终末期肾病的风险
研究纳入1837例2型糖尿病且eGFR>30 mL/min/1.73 m²的患者,中位随访8.6年,134例发生ESKD。校正心血管肾脏危险因素(含eGFR和白蛋白尿)后,基线尿液LRG1最高三分位组较低三分位组ESKD风险增加1.91倍(95%CI 1.04-3.50),连续变量每增加1个标准差校正风险增加1.53倍(95%CI 1.19-1.98),且该关联独立于血浆LRG1。
要点
- 尿液LRG1最高三分位组较低三分位组ESKD风险增加1.91倍(95%CI 1.04-3.50)。
- 尿液LRG1每增加1个标准差,ESKD校正风险增加1.53倍(95%CI 1.19-1.98)。
- 尿液LRG1与ESKD的关联独立于血浆LRG1、eGFR和白蛋白尿。
核心结论
- 尿液LRG1作为一种TGF-β信号调节因子,可独立于临床危险因素预测2型糖尿病患者进展至ESKD的风险,提示其可能是参与肾病进展病理生理通路的新因子。
研究设计与样本
- 研究从一家区域医院和一家初级保健机构招募1837例2型糖尿病且eGFR>30 mL/min/1.73 m²的参与者,采用生存分析评估尿液LRG1与ESKD风险的关联。
主要发现
- 中位随访8.6年(四分位距5.8-9.6年)期间,共发生134例ESKD事件。
- 校正包括eGFR和白蛋白尿在内的心血管肾脏危险因素后,基线尿液LRG1最高三分位组较低三分位组进展至ESKD的风险增加1.91倍(95%CI 1.04-3.50)。
- 尿液LRG1作为连续变量,每增加1个标准差与ESKD校正风险增加1.53倍相关(95%CI 1.19-1.98)。
- 尿液LRG1与ESKD的关联独立于血浆LRG1。
- 尿液LRG1与快速肾功能下降和进展至大量白蛋白尿相关,这两者是导致ESKD的常见途径。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Leucine-rich α-2 glycoprotein 1 (LRG1) was recently identified as an amplifier of transforming growth factor-β (TGF-β)-induced kidney fibrosis in animal models. We aimed to study whether urine LRG1 is associated with risk of progression to end-stage kidney disease (ESKD) in individuals with type 2 diabetes. RESEARCH DESIGN AND METHODS: A total of 1,837 participants with type 2 diabetes and estimated glomerular filtration rate (eGFR) >30 mL/min/1.73 m2 were recruited from a regional hospital and a primary care facility. Association of urine LRG1 with risk of ESKD (progression to sustained eGFR <15 mL/min/1.73 m2, dialysis, or death resulting from renal causes) was assessed by survival analyses. RESULTS: During a median follow-up of 8.6 (interquartile range 5.8-9.6) years, 134 incident ESKD events were identified. Compared with those in the lowest tertile, participants with baseline urine LRG1 in the highest tertile had a 1.91-fold (95% CI 1.04-3.50) increased risk of progression to ESKD, after adjustment for cardiorenal risk factors, including eGFR and albuminuria. As a continuous variable, 1 SD increment in urine LRG1 was associated with a 1.53-fold (95% CI 1.19-1.98) adjusted risk of ESKD. Of note, the association of urine LRG1 with ESKD was independent of plasma LRG1. Moreover, urine LRG1 was associated with rapid kidney function decline and progression to macroalbuminuria, two common pathways leading to ESKD. CONCLUSIONS: Urine LRG1, a TGF-β signaling modulator, predicts risk of progression to ESKD independently of clinical risk factors in patients with type 2 diabetes, suggesting that it may be a novel factor involved in the pathophysiological pathway leading to kidney disease progression.
引用
- Liu JJ, Liu S, Wang J, et al. Urine Leucine-Rich α-2 Glycoprotein 1 (LRG1) Predicts the Risk of Progression to End-Stage Kidney Disease in Patients With Type 2 Diabetes. Diabetes Care. 2023. PMID: 36516193. doi:10.2337/dc22-1611
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。